Back

Subcutaneous semaglutide and peripheral arterial occlusive disease in type 2 diabetes: network meta-analysis of randomized trials

31 August 2026 (08:25 - 08:35)
Organised by: Logo
Congress Presentation Part of: Modulation of risk and outcomes in peripheral artery disease Peripheral Artery Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Mohammad Movahed

University of Arizona - College of Medicine, Tucson (United States of America)

5 More presentations in this session

Presentation thumbnail
Multistate modeling of clinical trajectories and transition-specific risk patterns in peripheral artery disease
Doctor Y. ZHANG (Shatin, HK) Doctor G. Tan (Shatin, HK)
Abstract Slides
Presentation thumbnail
Adherence to statins with risk of cardiovascular and limb events in peripheral artery disease
Doctor M. Ude (Dallas, US)
Abstract Slides
Presentation thumbnail
Prevalence of high inflammatory risk (hsCRP ≥2 mg/L) in European patients with atherosclerotic cardiovascular disease with/without chronic kidney disease: sub-analysis of the global POSEIDON study
Professor D. Leistner (Frankfurt, DE)
Abstract Slides
Presentation thumbnail
A novel machine learning derived proteomics-leveraged panel to predict presence and prognosis of obstructive peripheral artery disease: the CASABLANCA Study
Professor J. Januzzi (Boston, US)
Abstract Slides
Presentation thumbnail
Effects of semaglutide on walking distance, symptoms and rescue treatment by baseline medical therapy and LDL cholesterol levels: insights from the STRIDE trial
Doctor M. Bonaca (Aurora, US)
Abstract Slides

Access the full session

Session thumbnail
Modulation of risk and outcomes in peripheral artery disease
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 08:25 CET
You may be interested in
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025
thumbnail
Congress Presentation
Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials
3 September 2019
thumbnail
Congress Presentation
Navigating lower limb PAD diagnosis and treatment
2 September 2024
thumbnail
Congress Presentation
Effect of glucagon-like peptide-1 receptor agonists on blood pressure: a systematic review and meta-analysis
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources